Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
06.06.ADHD drugs back in the spotlight after study debunks rising prevalence
06.06.Juvenescence enhances AI drug discovery with Ro5 acquisition
06.06.EC authorises Sydnexis' paediatric myopia treatment
05.06.Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
05.06.MHRA warns women using weight loss jabs must use effective contraception
05.06.Akeso gains NMPA approval for cadonilimab to treat cervical cancer
05.06.Introducing AI into the pharma supply chain is a journey
05.06.ePRO and eCOA: Digital solutions driving clinical trials engagement
05.06.Axxam and Molecular Health link for therapeutic targets
04.06.Ascletis's daily acne tablet set for China review after Phase III win
04.06.Redwire gains Aspera contract for space-based cancer research
04.06.Agenus and Zydus sign agreements for botensilimab and balstilimab
04.06.Magazine: Are regulators keeping pace with AI adoption in clinical trials?
04.06.Roche extends SMA market lead with Evrysdi tablet approval in Europe
04.06.EC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma
03.06.ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
03.06.SpyGlass Pharma secures $75m for ophthalmic drug delivery platform
03.06.ASCO25: Kura's Phase II ziftomenib results trigger NDA acceptance from FDA
03.06.ASCO25: Genmab's Rina-S en route to 'blockbuster potential' amid further positive data
03.06.FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia
03.06.Regeneron to acquire rights for Hansoh's HS-20094 therapy
02.06.BMS outlays $11bn to join BioNTech's development of bispecific cancer drug
02.06.Sanofi to expand immunology offerings with Blueprint Medicines
02.06.ASCO25: J&J's Carvykti shows strong efficacy across multiple myeloma risk groups
02.06.Sanofi and Regeneron report results from two Phase III trials of COPD treatment